Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
TPG explores $7.5bn Asia OneHealthcare exit with sale or IPO options
TPG explores $7.5bn Asia OneHealthcare exit with sale or IPO options TPG has appointed Malayan...
Blackstone teams with Dubai Aerospace on $1.6bn annual aircraft leasing push
Blackstone teams with Dubai Aerospace on $1.6bn annual aircraft leasing push Blackstone has...
CVC seeks co-investors for $12.7bn Recordati buyout in mega LBO push
CVC seeks co-investors for $12.7bn Recordati buyout in mega LBO push CVC Capital Partners is...